Annual CFO
-$10.07 M
+$1.34 M+11.72%
31 December 2023
Summary:
Yield10 Bioscience annual cash flow from operations is currently -$10.07 million, with the most recent change of +$1.34 million (+11.72%) on 31 December 2023. During the last 3 years, it has fallen by -$1.41 million (-16.27%). YTEN annual CFO is now -926.61% below its all-time high of -$980.70 thousand, reached on 31 December 2004.YTEN Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$574.00 K
+$329.00 K+36.43%
30 June 2024
Summary:
Yield10 Bioscience quarterly cash flow from operations is currently -$574.00 thousand, with the most recent change of +$329.00 thousand (+36.43%) on 30 June 2024. Over the past year, it has increased by +$2.04 million (+78.02%). YTEN quarterly CFO is now -454.32% below its all-time high of $162.00 thousand, reached on 30 September 2006.YTEN Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$5.80 M
+$2.50 M+30.17%
30 June 2024
Summary:
Yield10 Bioscience TTM cash flow from operations is currently -$5.80 million, with the most recent change of +$2.50 million (+30.17%) on 30 June 2024. Over the past year, it has increased by +$5.62 million (+49.22%). YTEN TTM CFO is now -127.77% below its all-time high of -$2.55 million, reached on 31 March 2006.YTEN TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
YTEN Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +11.7% | +78.0% | +49.2% |
| 3 y3 years | -16.3% | +71.2% | +33.8% |
| 5 y5 years | -15.0% | +58.0% | +22.4% |
YTEN Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -16.3% | +11.7% | at high | +81.5% | at high | +49.6% |
| 5 y | 5 years | -16.3% | +11.7% | at high | +82.1% | at high | +49.6% |
| alltime | all time | -926.6% | +68.5% | -454.3% | +95.3% | -127.8% | +83.3% |
Yield10 Bioscience Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2024 | - | -$574.00 K(-36.4%) | -$5.80 M(-30.2%) |
| Mar 2024 | - | -$903.00 K(-47.2%) | -$8.30 M(-17.5%) |
| Dec 2023 | -$10.07 M(-11.7%) | -$1.71 M(-34.5%) | -$10.07 M(-11.8%) |
| Sept 2023 | - | -$2.61 M(-15.2%) | -$11.42 M(-0.8%) |
| June 2023 | - | -$3.08 M(+15.4%) | -$11.51 M(+4.9%) |
| Mar 2023 | - | -$2.67 M(-12.9%) | -$10.97 M(-3.8%) |
| Dec 2022 | -$11.40 M(+23.2%) | -$3.06 M(+13.3%) | -$11.40 M(+5.3%) |
| Sept 2022 | - | -$2.70 M(+6.5%) | -$10.83 M(+7.0%) |
| June 2022 | - | -$2.54 M(-18.2%) | -$10.12 M(+4.1%) |
| Mar 2022 | - | -$3.10 M(+24.8%) | -$9.72 M(+5.0%) |
| Dec 2021 | -$9.25 M(+6.9%) | -$2.48 M(+24.7%) | -$9.25 M(+5.7%) |
| Sept 2021 | - | -$1.99 M(-6.9%) | -$8.76 M(-0.7%) |
| June 2021 | - | -$2.14 M(-18.9%) | -$8.82 M(-2.1%) |
| Mar 2021 | - | -$2.64 M(+32.6%) | -$9.01 M(+4.0%) |
| Dec 2020 | -$8.66 M(+0.1%) | -$1.99 M(-3.4%) | -$8.66 M(-12.3%) |
| Sept 2020 | - | -$2.06 M(-11.4%) | -$9.88 M(+7.5%) |
| June 2020 | - | -$2.32 M(+1.6%) | -$9.19 M(+6.3%) |
| Mar 2020 | - | -$2.29 M(-28.7%) | -$8.65 M(-0.1%) |
| Dec 2019 | -$8.65 M(-1.1%) | -$3.21 M(+134.6%) | -$8.65 M(+15.9%) |
| Sept 2019 | - | -$1.37 M(-23.2%) | -$7.47 M(-6.0%) |
| June 2019 | - | -$1.78 M(-22.4%) | -$7.94 M(-1.0%) |
| Mar 2019 | - | -$2.30 M(+13.5%) | -$8.02 M(-8.4%) |
| Dec 2018 | -$8.75 M(+6.7%) | -$2.02 M(+9.8%) | -$8.75 M(+1.5%) |
| Sept 2018 | - | -$1.84 M(-0.8%) | -$8.62 M(-2.0%) |
| June 2018 | - | -$1.86 M(-38.7%) | -$8.80 M(+0.1%) |
| Mar 2018 | - | -$3.03 M(+60.1%) | -$8.80 M(+7.3%) |
| Dec 2017 | -$8.20 M(-43.1%) | -$1.89 M(-6.4%) | -$8.20 M(-6.0%) |
| Sept 2017 | - | -$2.02 M(+9.2%) | -$8.73 M(-21.2%) |
| June 2017 | - | -$1.85 M(-23.8%) | -$11.07 M(+7.4%) |
| Mar 2017 | - | -$2.43 M(+0.7%) | -$10.31 M(-28.4%) |
| Dec 2016 | -$14.40 M(-34.1%) | -$2.42 M(-44.7%) | -$14.40 M(-17.5%) |
| Sept 2016 | - | -$4.37 M(+301.0%) | -$17.46 M(+0.6%) |
| June 2016 | - | -$1.09 M(-83.3%) | -$17.35 M(-20.1%) |
| Mar 2016 | - | -$6.53 M(+19.3%) | -$21.73 M(-0.6%) |
| Dec 2015 | -$21.86 M(-10.9%) | -$5.47 M(+28.3%) | -$21.86 M(-1.9%) |
| Sept 2015 | - | -$4.26 M(-22.0%) | -$22.29 M(-2.3%) |
| June 2015 | - | -$5.47 M(-17.9%) | -$22.82 M(+2.6%) |
| Mar 2015 | - | -$6.66 M(+13.0%) | -$22.23 M(-9.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2014 | -$24.54 M(-7.9%) | -$5.89 M(+22.9%) | -$24.54 M(-2.2%) |
| Sept 2014 | - | -$4.80 M(-1.7%) | -$25.08 M(-4.3%) |
| June 2014 | - | -$4.88 M(-45.6%) | -$26.20 M(-3.4%) |
| Mar 2014 | - | -$8.96 M(+39.3%) | -$27.11 M(+1.8%) |
| Dec 2013 | -$26.65 M(-16.0%) | -$6.43 M(+8.7%) | -$26.65 M(-3.2%) |
| Sept 2013 | - | -$5.92 M(+2.1%) | -$27.53 M(-1.3%) |
| June 2013 | - | -$5.80 M(-31.8%) | -$27.89 M(-0.3%) |
| Mar 2013 | - | -$8.50 M(+16.2%) | -$27.98 M(-11.9%) |
| Dec 2012 | -$31.74 M(+0.0%) | -$7.31 M(+16.4%) | -$31.74 M(-3.9%) |
| Sept 2012 | - | -$6.28 M(+6.7%) | -$33.03 M(-4.5%) |
| June 2012 | - | -$5.88 M(-52.0%) | -$34.58 M(-0.2%) |
| Mar 2012 | - | -$12.26 M(+42.4%) | -$34.63 M(+9.1%) |
| Dec 2011 | -$31.73 M(-0.8%) | -$8.61 M(+10.0%) | -$31.73 M(+1.7%) |
| Sept 2011 | - | -$7.83 M(+31.8%) | -$31.20 M(+2.4%) |
| June 2011 | - | -$5.94 M(-36.6%) | -$30.46 M(-4.6%) |
| Mar 2011 | - | -$9.36 M(+16.0%) | -$31.92 M(-0.2%) |
| Dec 2010 | -$32.00 M(+24.2%) | -$8.07 M(+13.8%) | -$32.00 M(+7.4%) |
| Sept 2010 | - | -$7.09 M(-4.0%) | -$29.79 M(-0.6%) |
| June 2010 | - | -$7.39 M(-21.7%) | -$29.97 M(+12.8%) |
| Mar 2010 | - | -$9.44 M(+61.0%) | -$26.57 M(+3.2%) |
| Dec 2009 | -$25.76 M(+40.1%) | -$5.86 M(-19.5%) | -$25.76 M(+9.2%) |
| Sept 2009 | - | -$7.28 M(+82.4%) | -$23.59 M(+3.7%) |
| June 2009 | - | -$3.99 M(-53.7%) | -$22.75 M(+0.9%) |
| Mar 2009 | - | -$8.63 M(+133.5%) | -$22.55 M(+22.6%) |
| Dec 2008 | -$18.39 M(+68.7%) | -$3.69 M(-42.6%) | -$18.39 M(+0.1%) |
| Sept 2008 | - | -$6.43 M(+69.4%) | -$18.37 M(+43.0%) |
| June 2008 | - | -$3.80 M(-14.9%) | -$12.84 M(+8.1%) |
| Mar 2008 | - | -$4.46 M(+21.6%) | -$11.87 M(+8.9%) |
| Dec 2007 | -$10.90 M(+202.5%) | -$3.67 M(+304.2%) | -$10.90 M(+33.7%) |
| Sept 2007 | - | -$908.00 K(-67.9%) | -$8.15 M(+15.1%) |
| June 2007 | - | -$2.83 M(-18.9%) | -$7.08 M(+55.7%) |
| Mar 2007 | - | -$3.49 M(+279.3%) | -$4.55 M(+26.2%) |
| Dec 2006 | -$3.60 M(-18.0%) | -$920.00 K(-667.9%) | -$3.60 M(+34.3%) |
| Sept 2006 | - | $162.00 K(-154.2%) | -$2.68 M(-5.7%) |
| June 2006 | - | -$299.00 K(-88.3%) | -$2.85 M(+11.7%) |
| Mar 2006 | - | -$2.55 M | -$2.55 M |
| Dec 2005 | -$4.39 M(+348.0%) | - | - |
| Dec 2004 | -$980.70 K | - | - |
FAQ
- What is Yield10 Bioscience annual cash flow from operations?
- What is the all time high annual CFO for Yield10 Bioscience?
- What is Yield10 Bioscience annual CFO year-on-year change?
- What is Yield10 Bioscience quarterly cash flow from operations?
- What is the all time high quarterly CFO for Yield10 Bioscience?
- What is Yield10 Bioscience quarterly CFO year-on-year change?
- What is Yield10 Bioscience TTM cash flow from operations?
- What is the all time high TTM CFO for Yield10 Bioscience?
- What is Yield10 Bioscience TTM CFO year-on-year change?
What is Yield10 Bioscience annual cash flow from operations?
The current annual CFO of YTEN is -$10.07 M
What is the all time high annual CFO for Yield10 Bioscience?
Yield10 Bioscience all-time high annual cash flow from operations is -$980.70 K
What is Yield10 Bioscience annual CFO year-on-year change?
Over the past year, YTEN annual cash flow from operations has changed by +$1.34 M (+11.72%)
What is Yield10 Bioscience quarterly cash flow from operations?
The current quarterly CFO of YTEN is -$574.00 K
What is the all time high quarterly CFO for Yield10 Bioscience?
Yield10 Bioscience all-time high quarterly cash flow from operations is $162.00 K
What is Yield10 Bioscience quarterly CFO year-on-year change?
Over the past year, YTEN quarterly cash flow from operations has changed by +$2.04 M (+78.02%)
What is Yield10 Bioscience TTM cash flow from operations?
The current TTM CFO of YTEN is -$5.80 M
What is the all time high TTM CFO for Yield10 Bioscience?
Yield10 Bioscience all-time high TTM cash flow from operations is -$2.55 M
What is Yield10 Bioscience TTM CFO year-on-year change?
Over the past year, YTEN TTM cash flow from operations has changed by +$5.62 M (+49.22%)